Literature DB >> 9144228

High-affinity binding of bioactive glycosylation-inhibiting factor to antigen-primed T cells and natural killer cells.

K Sugie1, T Nakano, T Tomura, K Takakura, T Mikayama, K Ishizaka.   

Abstract

High-affinity binding was demonstrated between suppressor-T-cell-derived bioactive glycosylation-inhibiting factor (GIF) and helper T hybridomas and natural killer cell line cells. Inactive GIF present in cytosol of suppressor T cells and Escherichia coli-derived recombinant human GIF (rhGIF) failed to bind to these cells. However, affinity of rhGIF for the target cells was generated by replacement of Cys-57 in the sequence with Ala or of Asn-106 with Ser or binding of 5-thio-2-nitrobenzoic acid to Cys-60 in the molecule. Such mutations and the chemical modification of rhGIF synergistically increased the affinity of GIF molecules for the target cells. The results indicated that receptors on the target cells recognize conformational structures of bioactive GIF. Equilibrium dissociation constant (Kd) of the specific binding between bioactive rGIF derivatives and high-affinity receptors was 10-100 pM. Receptors for bioactive GIF derivatives were detected on Th1 and Th2 T helper clones and natural killer NK1.1(+) cells in normal spleen but not on naive T or B cells. Neither the inactive rGIF nor bioactive rGIF derivatives bound to macrophage and monocyte lines or induced macrophages for tumor necrosis factor alpha production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144228      PMCID: PMC24669          DOI: 10.1073/pnas.94.10.5278

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

Review 1.  Mouse NK1.1+ T cells: a new family of T cells.

Authors:  A P Vicari; A Zlotnik
Journal:  Immunol Today       Date:  1996-02

2.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

3.  Conversion of inactive glycosylation inhibiting factor to bioactive derivatives by modification of a SH group.

Authors:  T Nakano; H Watarai; Y C Liu; Y Oyama; T Mikayama; K Ishizaka
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

4.  Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor.

Authors:  T Mikayama; T Nakano; H Gomi; Y Nakagawa; Y C Liu; M Sato; A Iwamatsu; Y Ishii; W Y Weiser; K Ishizaka
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

5.  Requirement of posttranslational modifications for the generation of biologic activity of glycosylation-inhibiting factor.

Authors:  Y C Liu; T Nakano; C Elly; K Ishizaka
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

6.  Biochemical characterization of antigen-specific glycosylation-inhibiting factor from antigen-specific suppressor T cells. II. The 55-kDa glycosylation-inhibiting factor peptide is a derivative of TCR alpha-chain and a subunit of antigen-specific glycosylation-inhibiting factor.

Authors:  Y Ishii; T Nakano; K Ishizaka
Journal:  J Immunol       Date:  1996-03-01       Impact factor: 5.422

7.  Biochemical characterization of antigen-specific glycosylation-inhibiting factor from antigen-specific suppressor T cells. I. Identification of a 55-kilodalton glycosylation-inhibiting factor peptide with TCR alpha-chain determinant.

Authors:  T Nakano; Y Ishii; K Ishizaka
Journal:  J Immunol       Date:  1996-03-01       Impact factor: 5.422

8.  Association of the "major histocompatibility complex subregion" I-J determinant with bioactive glycosylation-inhibiting factor.

Authors:  T Nakano; Y C Liu; T Mikayama; H Watarai; M Taniguchi; K Ishizaka
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

9.  The crystal structure of human glycosylation-inhibiting factor is a trimeric barrel with three 6-stranded beta-sheets.

Authors:  Y Kato; T Muto; T Tomura; H Tsumura; H Watarai; T Mikayama; K Ishizaka; R Kuroki
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

10.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.

Authors:  T Calandra; J Bernhagen; R A Mitchell; R Bucala
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more
  5 in total

1.  Deficiency of the macrophage migration inhibitory factor gene has no significant effect on endotoxaemia.

Authors:  N Honma; H Koseki; T Akasaka; T Nakayama; M Taniguchi; I Serizawa; H Akahori; M Osawa; T Mikayama
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

2.  Posttranslational modification of the glycosylation inhibiting factor (GIF) gene product generates bioactive GIF.

Authors:  H Watarai; R Nozawa; A Tokunaga; N Yuyama; M Tomas; A Hinohara; K Ishizaka; Y Ishii
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

3.  CD4 cell-secreted, posttranslationally modified cytokine GIF suppresses Th2 responses by inhibiting the initiation of IL-4 production.

Authors:  Misa Kim-Saijo; Edith M Janssen; Katsuji Sugie
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-26       Impact factor: 11.205

4.  Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation.

Authors:  Xiaocai Yan; Rimas J Orentas; Bryon D Johnson
Journal:  Cytokine       Date:  2006-03-07       Impact factor: 3.861

Review 5.  Post-translational regulation of macrophage migration inhibitory factor: Basis for functional fine-tuning.

Authors:  Lisa Schindler; Nina Dickerhof; Mark B Hampton; Jürgen Bernhagen
Journal:  Redox Biol       Date:  2017-12-06       Impact factor: 11.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.